Top-notch biotech stock Dyne Therapeutics (DYN) broke out Monday after the company unveiled promising test results for a pair of muscular dystrophy treatments. Dyne stock catapulted 22.4% to 33.89. Shares hit a record high, topping a buy point at 30.27 out of a consolidation, according to MarketSurge. The biotech stock's relative strength line also launched to a new high. X Top 2% Biotech Stock Dyne studied drugs it calls DYNE-101 and DYNE-251 in patients with myotonic dystrophy type 1 and Duchenne muscular ...